Phase 3 Triple-Negative Breast Cancer Clinical Trials
19 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–19 of 19 trials
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled350 locationsNCT05633654
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled299 locationsNCT06393374
Recruiting
Phase 3
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.524 enrolled1 locationNCT06279364
Recruiting
Phase 3
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
Triple-Negative Breast CancerBreast Cancer Stage IV
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University246 enrolled7 locationsNCT06889688
Recruiting
Phase 3
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Triple-Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd364 enrolled1 locationNCT07533123
Recruiting
Phase 3
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Triple-Negative Breast Cancer
Fudan University134 enrolled1 locationNCT05806060
Recruiting
Phase 3
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
TNBC - Triple-Negative Breast Cancer
West China Hospital318 enrolled1 locationNCT06627712
Recruiting
Phase 3
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Breast CancerTriple-Negative Breast Cancer
Fudan University764 enrolled15 locationsNCT05909332
Recruiting
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832
Recruiting
Phase 3
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
Triple-Negative Breast Cancer
Sun Yat-Sen University Cancer Center228 enrolled1 locationNCT04722978
Recruiting
Phase 3
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Triple-Negative Breast Cancer
West German Study Group348 enrolled42 locationsNCT06081244
Recruiting
Phase 3
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Fudan University606 enrolled1 locationNCT05862064
Recruiting
Phase 3
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
Triple-Negative Breast CancerMetastatic Breast Cancer
UNICANCER96 enrolled1 locationNCT05552001
Recruiting
Phase 3
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Triple-Negative Breast CancerCervical CancerUrothelial Carcinoma+12 more
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Triple-Negative Breast Cancer
Jina Pharmaceuticals Inc.657 enrolled4 locationsNCT03671044
Recruiting
Phase 3
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
Triple-Negative Breast Cancer
Guangdong Provincial People's Hospital310 enrolled1 locationNCT06533384
Recruiting
Phase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
Fudan University424 enrolled2 locationsNCT05999149
Recruiting
Phase 3
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Triple-Negative Breast Cancer
Fudan University223 enrolled1 locationNCT05760378
Recruiting
Phase 3
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Triple-Negative Breast CancerMetastatic Breast CancerMutation
Fudan University203 enrolled1 locationNCT05954442